Surgical Oncologists as Scientists (SOAS) Training Program

项目摘要/摘要 改善患者健康的转化性癌症研究需要多学科的方法来推进 从(A)基础研究到(B)临床前验证(通常利用生物库组织)的创新发现 (C)通过创业和商业化进行临床实施。但外科医生很少会收到正式的 在生物库和创业方面的培训，很少有项目是为了正式培训外科医生 癌症生物学与肿瘤微环境(TME)认识到这些在培训外科医生方面的关键差距- 科学家、外科和摩尔癌症中心(NCI-指定综合癌症 中心)和加州大学圣地亚哥分校(加州大学圣地亚哥分校)外科系提出了一项新的 支持对MD/DO外科医生进行培训的计划--那些有客观证据表明致力于 在一个为期两年的培训计划中从事学术外科肿瘤学。我们将打造外科肿瘤学家 AS科学家培训计划以三个主题的正式培训为中心：1)TME；2)生物库； 3)创新/创业。TME培训的理由是，越来越多的肿瘤外科医生- 科学家需要彻底了解TME如何在癌症启动过程中发挥重要作用的细节， 进展、转移、对治疗的反应，并作为抗癌药物的新靶点。其基本原理是 对于生物库的培训，学术外科医生经常被要求在研究中合作，因为 他们无与伦比地获得人类标本，这些标本必须适当地存放在一个专门的生物储存库中。 最后，创新/创业培训的基本原理涉及确保 外科医生-科学家的研究培训具有现实世界的翻译相关性-也就是说，我们需要证明 改善癌症护理，而不仅仅是提高理解。这一理论基础充分利用了圣地亚哥大都市 区域是成功翻译(即商业化)所需的第三大组件组装 食品和药物管理局(FDA)批准的临床现实的创新。圣地亚哥有太多的 生物技术初创公司(数百家从加州大学圣地亚哥分校剥离出来)、天使投资者、私募股权和风险资本 公司、合同研究组织和本地网络活动。SOAS计划将由一位 外科肿瘤学家/转化学家和博士科学家带来了互补但独特的技能 创新中的科学和经验。研究性培训将在14名教师导师之一内进行 实验室，每个实验室都有坚实的、持续的R01 NIH资金，并且每个实验室都有很好的成功记录 师徒关系。此外，学员将与我们9家企业家中的至少一家建立共同指导关系 联络顾问，每个人都有翻译方面的实际经验(例如，专利、初创企业)。面向社会的服务 培训计划将培训合作外科医生-科学家，使其成为未来学术外科和 肿瘤学积极参与将创新发现转化为临床癌症治疗。

PROJECT SUMMARY / ABSTRACT Translational cancer research that improves patient health requires a multi-disciplinary approach that advances innovative discoveries from (A) basic research to (B) preclinical validation (often utilizing biobanked tissue) to (C) clinical implementation via entrepreneurship and commercialization. But surgeons rarely receive formal training in biobanking and entrepreneurship, and few programs are designed to formally train surgeons in the cancer biology and the tumor microenvironment (TME). Recognizing these critical gaps in training surgeon- scientists, the Department of Surgery and the Moores Cancer Center (NCI-Designated Comprehensive Cancer Center) and the Department of Surgery at the University of California San Diego (UC San Diego) propose a new program to support training for MD/DO surgeon-scientists who show objective evidence of a commitment to a career in academic surgical oncology for a two-year training program. We will create the Surgical Oncologists as Scientists (SOAS) Training Program centered on formal training in three topics: 1) the TME; 2) biobanking; and 3) innovation/entrepreneurship. The rationale for TME training is that increasingly, the oncologic surgeon- scientist needs to thoroughly understand details of how the TME plays significant roles in cancer initiation, progression, metastasis, response to therapies, and serves as novel targets for anti-cancer drugs. The rationale for training in biobanking is that academic surgeons are frequently asked to collaborate in research because their unparalleled access to human specimens, which must be properly banked in a dedicated biorepository. Finally, the rationale for innovation/entrepreneurship training involves the critical need to ensure that research training of surgeon-scientists has real-world translational relevance—that is, we need to demonstrably improve cancer care, not merely improve understanding. This rationale leverages the metropolitan San Diego area as the third largest assembly of components necessary to successfully translate (i.e., commercialize) innovations into Food and Drug Administration (FDA)-approved clinical realities. San Diego includes a plethora of biotech startups (hundreds spun out of UC San Diego), Angel investors, private equity and venture capital firms, contract research organizations, and local networking activities. The SOAS program will be co-led by a surgical oncologist/translational scientist and a PhD scientist that bring complementary, but unique skills in science and experience in innovation. Research training will occur within one of 14 Faculty Mentor’s laboratories, each of which has solid, continuous R01 NIH funding, and each has a strong record of successful mentorship. Also, Trainees will develop co-mentoring relationships with at least one of our 9 Entrepreneurial Liaison Advisors, each of whom has practical experience with translation (e.g., patents, start-ups). The SOAS Training Program will train collaborative surgeon-scientists to become future leaders in academic surgery and oncology to actively participate in translating innovative new discoveries into clinical cancer care.